Ibiglustat succinate

Catalog No.E0646 Batch:E064601

Print

Technical Data

Formula

C20H24FN3O2S.C4H6O5
Molecular Weight 523.58 CAS No. 1629063-78-0
Solubility (25°C)* In vitro DMSO 100 mg/mL (190.99 mM)
Water 100 mg/mL (190.99 mM)
Ethanol 100 mg/mL (190.99 mM)
In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ibiglustat succinate (Venglustat succinate) is a glucosylceramide (GlcCer) synthase inhibitor that blocks the formation of glucosylceramide.
Targets
GlcCer synthase
In vitro

Ibiglustat succinate can prevent additional globotriaosylceramide(GL-3) accumulation and could serve to ameliorate the abundant levels of this sphingolipid in fabry disease cardiomyocytes.
In Vivo

Venglustat administration significantly reduces the accumulation of glycosphingolipids and pathological α-synuclein aggregates in the central nervous system and ameliorated the associated memory deficit.

Protocol (from reference)

Cell Assay:

[2]
  • Cell Lines

    Fabry disease cardiomyocytes

  • Concentrations

    1 μM

  • Incubation Time

    15 days

  • Method

    Embryoid bodies (EBs) are treated with 1 μM Ibiglustat succinate for 15 days. Culture medium with this compound is replaced every 2 days during the 15 days of treatment. GL-3 clearance is tested once the GL3 accumulation reached the plateau. Twenty-eight days after the start of differentiation, beating EBs are treated with 1 μM of this chemical for 15 days or with 0.3 μg/ml of agalsidase beta for 5 days. Culture media with this compound or agalsidase beta are replaced every 2 days. GL-3 accumulation is investigated by immunocytological (ICC), electron microscopy (EM), and mass spectrometry (MS) analysis.
Animal Study:

[3]
  • Animal Models

    Gaucher disease model mice(C57Bl/6)

  • Dosages

    0.03%, 0.033%

  • Administration

    p.o.

References

  • https://pubmed.ncbi.nlm.nih.gov/29614425/
  • https://pubmed.ncbi.nlm.nih.gov/24850378/
  • https://pubmed.ncbi.nlm.nih.gov/34686711/

Sellecks Ibiglustat succinate Has Been Cited by 1 Publication

Human iPSC-derived renal collecting duct organoid model cystogenesis in ADPKD [ Cell Rep, 2023, 42(12):113431] PubMed: 38039961

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.